NASDAQ
Inhibitor Therapeutics, Inc. (INTI) has a free cash flow growth of -80.40% as of Friday, May 29, 2026. This represents a 1407.16% decrease compared to its 12-month average of -5.33%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.